Full-Time
Posted on 8/27/2025
Off-the-shelf gamma delta T therapies
$56.73 - $78.85/hr
San Carlos, CA, USA
Hybrid
Employees are required to be onsite at least three days per week (Tuesday–Thursday mandatory).
| , |
Adicet Bio develops cancer immunotherapies using donor-derived, allogeneic gamma delta T cells that are engineered to target and kill cancer cells. The therapy uses off-the-shelf cells instead of a patient’s own cells, making treatment faster and potentially more readily available. The product works by introducing these modified T cells into a patient, where they seek out and destroy tumor cells. Adicet Bio differentiates itself by providing an immediately available, genetically modified immune cell therapy rather than patient-specific treatments, and by focusing on gamma delta T cells, which may offer targeted anti-tumor activity with a different safety and efficacy profile. The company aims to bring these therapies to patients through commercialization, licensing, and partnerships with healthcare providers and larger pharma companies, supported by ongoing research and development and strategic initiatives like the merger with resTORbio and a substantial funding round.
Company Size
51-200
Company Stage
IPO
Headquarters
Redwood City, California
Founded
2014
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Flexible Work Hours
Paid Vacation
Paid Sick Leave
Paid Holidays
Parental Leave
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Wellness Program
Adicet Bio has expanded enrollment in its Phase 1 prula-cel programme for autoimmune diseases to over 20 patients as of 31 December 2025, more than doubling since October. All seven autoimmune cohorts are now actively enrolling, including the first ANCA-associated vasculitis patient. The company has secured FDA alignment for outpatient dosing of lupus nephritis and systemic lupus erythematosus patients. Adicet is also advancing ADI-212 for metastatic castration-resistant prostate cancer, targeting a regulatory filing in the first half of 2026. An October 2025 equity raise of approximately $74.8 million has extended the company's cash runway into the second half of 2027. Multiple clinical data updates are planned throughout 2026 as Adicet works towards a pivotal trial design.
Adicet Bio (NASDAQ:ACET) announced an $80 million stock offering, pricing 70,001,000 shares at $1 each and pre-funded warrants for 10 million shares at $0.9999. The offering, expected to close by October 8, 2025, aims to bolster finances amid rapid cash burn. Jefferies and Guggenheim Securities are joint book-running managers. Adicet also reported positive results from its ADI-001 trial and halted ADI-270 development, reducing its workforce by 30% to extend cash reserves into Q4 2026.
Auspicious alliance: MaxCyte and Adicet partner to develop off-the-shelf T-cell therapies.
MaxCyte (NASDAQ:MXCT) has signed a strategic platform license agreement with Adicet Bio for the use of MaxCyte's Flow Electroporation(R) technology and ExPERT(TM) platform.
Adicet Bio receives FDA Fast Track Designation for ADI-001 in systemic sclerosis treatment.